Belvedere Trading
ZVRA icon

Belvedere Trading’s Zevra Therapeutics ZVRA Stock Holding History

Belvedere Trading’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,100
Closed -$96.1K – 1111
2025
Q3 		$96.1K Buy
+10,100
New +$101K ﹤0.01% 593

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Belvedere Trading's ZVRA Position: Q4 2025 in Review

Belvedere Trading sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 6,239 shares — an estimated $59.3K sold.

Belvedere Trading first reported a position in ZVRA in Q3 2021 and held it in 3 quarters. The position peaked at $220K in Q4 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Belvedere Trading reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Belvedere Trading sold 6,239 Zevra Therapeutics shares in Q4 2025, an estimated $59.3K.
  • Belvedere Trading first reported a position in Zevra Therapeutics in Q3 2021 and held it in 3 quarters.
  • Belvedere Trading's Zevra Therapeutics position peaked at $220K in Q4 2021.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.